NUTX

Several events have impacted Nutex Health's stock price in the past six months. Strong Q1 2026 earnings and a share repurchase program led to a positive stock reaction. BlackRock, Inc. disclosed a new 5.3% passive stake in Nutex Health, contributing to a rise in the stock price. Unusually high arbitration costs in Q1 2026 led to a decline in adjusted EBITDA, though management expects these costs to normalize. Full-year 2025 financial results showed an increase in total revenue and EBITDA, and the company initiated a second stock repurchase program. A short seller report issued in November 2025 created negative sentiment and impacted stock price.